PLSE PULSE BIOSCIENCES, INC.
Price Chart
Executive Summary
Pulse Biosciences presented positive late-breaking clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at Heart Rhythm 2026. Key findings include sustained 100% procedural success at 6 months, 96% at one year, and a 90% Kaplan-Meier estimate of freedom from atrial fibrillation, flutter, or tachycardia at one year, along with consistently efficient procedural performance and a maintained low serious adverse event rate of 1.7%.
Actionable Insight
Monitor for further clinical trial updates and regulatory milestones, as these positive results could influence future investment and partnership opportunities for Pulse Biosciences.
Key Facts
- Sustained 100% procedural success of evaluable patients by holter at 6 months (95/95)
- Sustained 96% procedural success of evaluable patients by holter at one year (51/53)
- Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year
- Left atrial dwell time: 18.6 ± 13.0 minutes
- Total procedure time: 60.2 ± 27.7 minutes
- Fluoroscopy time: 9.4 ± 5.9 minutes
- Average applications per-patient for PVI: 12.3 ± 2.6
- Safety profile: 1.7% (3/177) of subjects experienced a SAE related to the primary safety endpoint
Financial Impact
No direct financial impact reported; the data is clinical and relates to the performance of the nPulse Cardiac Catheter System.
Risk Factors
- The data is from a first-in-human feasibility study with a limited cohort size (177 patients treated), so larger trials are needed to confirm these results.
- The long-term durability and safety of the nPulse Cardiac Catheter System beyond one year are not yet established.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-013383 |
| Exhibit: ex_950223.htm | 0001437749-26-013383 |
| Document: 0001437749-26-013383-index-headers.html | 0001437749-26-013383 |
| Document: 0001437749-26-013383-index.html | 0001437749-26-013383 |
| Document: 0001437749-26-013383.txt | 0001437749-26-013383 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Institutional Cluster
| $26.89 awaiting T+5 | awaiting T+5 | — | $24.37 (−9.37%) |
|
Jun 10, 2026
2d ago
|
8-K
| $25.79 awaiting T+5 | awaiting T+5 | — | $24.37 (−5.51%) |
|
May 15, 2026
28d ago
|
Insider Cluster
| $25.61 $26.00 | ▲ +1.52% | ▼ −0.10% | $24.37 (−4.84%) |
|
May 11, 2026
4w ago
|
Insider Cluster
| $19.08 $25.61 | ▲ +34.22% | ▲ +34.31% | $24.37 (+27.73%) |
|
May 11, 2026
4w ago
|
Insider Cluster
| $19.08 $25.61 | ▲ +34.22% | ▲ +34.31% | $24.37 (+27.73%) |
|
May 6, 2026
5w ago
|
8-K
| $19.21 $23.30 | ▲ +21.29% | ▲ +20.16% | $24.37 (+26.86%) |
|
May 4, 2026
5w ago
|
8-K
| $20.03 $19.08 | ▼ −4.74% | ▼ −7.68% | $24.37 (+21.67%) |
|
Apr 27, 2026
6w ago
|
8-K
| $22.65 $20.03 | ▼ −11.57% | ▼ −11.97% | $24.37 (+7.59%) |
|
Apr 16, 2026
8w ago
|
8-K
| $20.51 $24.25 | ▲ +18.23% | ▲ +17.25% | $24.37 (+18.82%) |
|
Apr 9, 2026
9w ago
|
8-K
| $19.25 $20.51 | ▲ +6.55% | ▲ +3.36% | $24.37 (+26.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access